LIC: Acquires 2.015% Stake in Info Edge, Holding Rises to 5.008%

Life Insurance Corporation of India (LIC) has disclosed the acquisition of an additional 2.015% of the equity share capital of Info Edge (India) Ltd. This transaction brings LIC’s total shareholding in Info Edge to 5.008%. The acquisition was executed through market purchases, signifying LIC’s continued investment in the online classifieds and real estate listings company. The disclosure adheres to SEBI’s substantial acquisition regulations.

LIC Increases Stake in Info Edge (India) Ltd

Life Insurance Corporation of India (LIC) has announced the acquisition of a substantial number of shares in Info Edge (India) Ltd, a leading Indian e-commerce company. The disclosure, made in accordance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, indicates that LIC has acquired an additional 12,944,498.00 shares, representing 2.015% of the company’s total equity share capital.

Holding Crosses 5% Threshold

Following this acquisition, LIC’s total holding in Info Edge (India) Ltd has increased to 32,349,605.00 shares, which constitutes 5.008% of the total voting capital. Prior to this transaction, LIC held 5.008% shares. The acquisition took place through market purchases, specifically a Market Sale, between the dates of October 16, 2026, and December 21, 2022. The total diluted share capital of Info Edge remains unchanged at 1,296,841,200.00.

Disclosure Details

The filing provides a comprehensive breakdown of the acquisition, including the number of shares acquired and the resultant percentage holding. LIC’s Investment Department, operating from its Central Office in Mumbai, made the disclosure. The disclosure is crucial for regulatory compliance and provides transparency to investors regarding significant changes in shareholding patterns of listed companies. The acquisition signifies LIC’s confidence in Info Edge’s business prospects.

Source: BSE

Previous Article

Rama Shiva Lease Finance: Reports 4.04% Stake Acquisition in Biogen Pharmachem

Next Article

Zydus Wellness: Clarifies FSSAI Notice on Product Label Claims